ASCO 2020: Nivolumab plus ipilimumab combination for previously treated kidney cancer
Results from the phase II FRACTION-RCC clinical trial to assess [...]
Results from the phase II FRACTION-RCC clinical trial to assess [...]
Results from a phase II study of bevacizumab and erlotinib [...]
Two studies were presented during the 2020 American Society of [...]
Biomarkers enable doctors predict which patients will respond to which [...]
Results from a phase II international trial led by researchers [...]
A study presented during the 2020 American Society of Clinical [...]
Updated results from the KEYNOTE-426 study of pembrolizumab plus axitinib [...]
In a study presented during the 2020 American Society of [...]
The following interviews with kidney cancer experts were recorded by [...]
New 30-month survival data from the CheckMate 214 study were [...]